Ibrutinib: The BTK Inhibitor Used for Hematologic Maligancies.

  Mr. Tanish V. Jain*, Mr. Kunal M. Jain, Dr.Rahul B. Lovhare, Dr.S.P.Pawar

P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India.

*Correspondence: tanjain2345@gmail.com, Tel: 8855953564

DOI: https://doi.org/10.71431/IJRPAS.2025.4408  

INTRODUCTION

The accepted treatment for chronic lymphocytic leukemia (CLL) has been chemotherapy. But in the modern period, its limits are becoming progressively more obvious. Numerous therapeutic targets have been identified as a result of the thorough investigation of carcinogenesis and other features of cancer cells. The small-molecule inhibitor ibrutinib is one such tailored medication that has revolutionized the way indolent lymphoma is treated.[1] Ibrutinib is a very strong, irreversible, and specific small-molecule inhibitor of Btk that is taken orally.[2] It inhibits the enzymatic activity of Btk by forming a covalent connection with a cysteine residue (CYS-481) at the Btk active site.[3] By preventing its autophosphorylation at Tyr-223, ibrutinib also prevents Btk from being fully activated. [4] This inhibition stops the BCR pathway from being activated downstream, which stops malignant B cells from growing, proliferating, and surviving.[5] Ibrutinib dissolves in aqueous buffers just little. It can melt between 149 and 158 degrees Celsius. Action mechanism Bruton's tyrosine kinase is selectively and covalently inhibited by ibrutinib. A review of the literature shows that there are no colorimetric or spectroscopic techniques available to quantify Ibrutinib,either for bulk medication or for the dosage forms used in pharmaceuticals. Since the goal of the current work was to design and validate techniques in accordance with ICH criteria, the methods were developed and validated in accordance with ICH guidelines for robustness, accuracy, precision, reproducibility, and ruggedness.[6] Behind Spleen associated tyrosine kinase[SYK], BTK holds a crucial role in the BCR pathway (Figure 1.1). When Syk activates BTK, its PH domain facilitates conformational changes and translocation to the cell membrane. BTK undergoes autophosphorylation at a conserved tyrosine residue in its kinase domain (Y551) in the membrane, where it is accessible to its substrate molecules.[7] The BCR signaling cascade is then propagated by activated BTK phosphorylating several downstream substrates. Upon phosphorylation, phospholipase Cγ2 (PLCγ2), one of the main substrates of BTK, becomes activated. PIP2 is broken down by activated PLCγ2 into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG stimulates protein kinase C (PKC), which in turn controls a number of downstream signaling pathways involved in cellular responses, whereas IP3 causes the release of calcium from intracellular reserves, resulting in calcium mobiliz.

                                               Fig:-1.1 BTK Signalling Pathway

The BCR pathway's signalling cascade downstream of Bruton's tyrosine kinase (BTK) is shown schematically, emphasizing key substrates that promote B cell survival, activation, proliferation, and differentiation. BTK phosphorylates phospholipase Cγ2 (PLCγ2) upon BCR interaction, resulting in the production of DAG (diacylglycerol) and inositol 1,4,5-trisphosphate (IP3). DAG stimulates PKC (protein kinase c), whereas IP3 mobilizes intracellular calcium. The rat sarcoma (RAS) pathway is further stimulated by this activation, which in turn activates transcription factors (myelocytomatosis) MYC and ETS-like kinase (ELK) as well as extracellular signal-regulated kinase (ERK). Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is translocated to the nucleus as a result of PKC activating the inhibitor of the nuclear factor-κB kinase (IKK) complex. This promotes the expression of genes necessary for Bcell survival and proliferation.[8]

Waldenstrom’s macroglobulinemia[WM] is a diverse illness that can manifest as amyloidosis, cryoglobulinemia, neuropathy, hyperviscosity, cytopenias, lymphadenopathy, or hepatosplenomegaly.[9] Despite the fact that people with WM typically live for years or even decades, the illness is incurable, and the majority of patients experience symptomatic disease recurrences that impair their quality of life and everyday activities. Because WM treatment is not standardized, the patient's age, symptoms, comorbidities, and preferences all play a role in the highly individualized therapy selection. After extensive basic, translational, and clinical research, ibrutinib's approval in WM marks a significant milestone. This review's goals are to outline the part BTK plays in the pathophysiology of WM, go over the preclinical and clinical evidence that helped ibrutinib get approved, and go over the experience with ibrutinib's clinical use in WM. [10]For people with mantle cell lymphoma, the current recommended daily dosage is 560 mg; for those with CLL/small lymphocytic lymphoma and Waldenström's macroglobulinemia.[11,12,13,14] In clinical trials, ibrutinib has also been used in combination with bendamustine and rituximab, as well as with the anti-CD20 monoclonal antibodies rituximab or ofatumumab.[15-18]Upon starting treatment, ibrutinib is frequently linked to asymptomatic lymphocytosis. Since ibrutinib interferes with integrin-mediated adhesion and the homing of malignant B cells to the lymphoid milieu, lymphocytosis has been identified as an inherent part of its mechanism of action. Even when the disease persists for months, it does not require special treatment. [19]

MOA:. It functions through building an irreversible bond with the cysteine residue in the active site of BTK at position 481 (Cys481). Because of this covalent bond, ATP cannot reach the active site, which inhibits BTK's kinase activity and interferes with downstream signaling that is necessary for B-cell survival and proliferation. Based on the [fig 1.2].The crystallographic representation of Ibrutinib binding to Bruton's tyrosine kinase (BTK).  

1. Covalent Binding to Cysteine 481 (Cys481):
• Ibrutinib forms an irreversible covalent bond with Cys481 in BTK’s active site.
• This prevents ATP from binding, leading to sustained inhibition of BTK activity.
2. Key Residues in Interaction:
• The figure highlights several amino acid residues such as Phe540, Glu475, Thr474, Met477, Lys430, Asp539, Ser538, and Leu542.
• These residues likely contribute to stabilizing the drug in the active site through hydrogen bonding and hydrophobic interactions.
3. Effect on BTK Signaling Pathway:
• By blocking BTK, Ibrutinib inhibits B-cell receptor (BCR) signaling.
• This disrupts malignant B-cell survival, migration, and adhesion, which is beneficial in treating B-cell malignancies like CLL and MCL.[20]

Fig:-1.2 3-D interaction diagram of  ibrutinib in the catalytic domain of BTK.

Factor affecting: Prognostic factor analysis revealed that baseline risk variables had no effect on ibrutinib activity; however, patients with TP53 and SF3B1 mutations or more than two previous treatments tended to have shorter PFS. In individuals with TN-CLL, ibrutinib monotherapy produced even better outcomes.[21]

FOOD AND DRUG INTERACTIONS

Food consumption affects the pharmacokinetics of ibrutinib. When administered during a fast, the drug's exposure is about 60% more than when taken with food. In particular, comparable pharmacokinetic profiles are obtained whether ibrutinib is taken 30 minutes prior to, 30 minutes following, or 2 hours following a high-fat meal. When compared to fed settings, the maximum concentration (Cₘₐₓ) and area under the curve (AUC) in individuals with chronic lymphocytic leukemia (CLL) are 43% and 61% lower, respectively, when fasting.Reduced first-pass metabolism in the liver and intestines, which results in enhanced bioavailability, is probably the cause of the increased exposure when taken with food. ​

The primary metabolizer of ibrutinib is cytochrome P450 3A4 (CYP3A4). Ibrutinib plasma concentrations can rise sharply when co-administered with strong or moderate CYP3A4 inhibitors, increasing the possibility of side effects. On the other hand, CYP3A4 inducers may lower ibrutinib levels, which could jeopardize its effectiveness.[22]

To maximize ibrutinib's therapeutic effectiveness and reduce any hazards, it is essential to comprehend how it interacts with food and other medications. Ibrutinib's bioavailability is increased when taken with meals, and it should be used with caution if you're taking it with medications that interfere with CYP3A4 action.[23]

IN VITRO EVALUATION

In vitro tests of this medication revealed that ibrutinib totally inhibit the BAT, IL-4 production, and FcεRI-dependent basophil release of histamine and leukotrienes.

Pharmacokinetics

1. Absorption Oral Bioavailability: When taken during a fast, ibrutinib has an absolute oral bioavailability of around 2.9%. When taken with food, its bioavailability rises dramatically. Drugs.Time to Peak Concentration (Tₘₐₓ): Ibrutinib takes 1 to 2 hours to reach its peak plasma concentration after oral dosing. ​Effect of Food: When compared to administration following an overnight fast, consuming a high-fat, high-calorie meal (800–1000 calories, with roughly 50% of calories from fat) increases the peak plasma concentration (Cₘₐₓ) by 2–4 times and the area under the curve (AUC) by 2 times.

2.Distribution:- Distribution of Plasma Protein Binding: Ibrutinib exhibits a high level of binding to plasma proteins, of about 97.3%.The drug's volume of distribution (Vₛ) is estimated to be around 10,000 liters, which indicates that it is widely distributed throughout the body.

3.The metabolism :-Primary Metabolic Pathways: The liver's CYP3A enzyme system is principally responsible for the metabolism of ibrutinib, with CYP2D6 playing a minor role.PCI-45227, a dihydrodiol metabolite, is the active metabolite of ibrutinib. Compared to ibrutinib itself, this metabolite has Bruton's tyrosine kinase (BTK) inhibitory action that is roughly 15 times lower. Metabolite to Parent Ratio: At steady-state, PCI-45227's mean metabolite to parent ratio ranges from 1 to 2.8.

4. Excretion:-

Elimination Half-Life Ibrutinib has a relatively short half-life in the body, with an elimination half-life of roughly 4 to 6 hours. ​
Routes of Excretion:
Feces: Mostly in the form of metabolites, over 80% of ibrutinib is eliminated in the feces. Less than 1% of the medication gets eliminated unaltered.
Urine: Mostly in the form of metabolites, less than 10% is eliminated in the urine.[24,25]

Pharmacogenetics

Genetic Variants of CYP3A4 Metabolic Variability: The cytochrome P450 enzyme CYP3A4 is the main enzyme responsible for the metabolism of ibrutinib. Ibrutinib metabolism and systemic exposure may be impacted by changes in CYP3A4 enzyme activity caused by genetic polymorphisms. ​
Impact of variations: Research has shown several CYP3A4 variations, including CYP3A4.17 and CYP3A4.24, that show no discernible enzyme activity, which may result in decreased ibrutinib metabolism and elevated drug levels.Impact of Variants in CYP3A5 Expression on Metabolism: CYP3A5 is an additional enzyme implicated in the metabolism of ibrutinib. Ibrutinib clearance may be impacted by changed enzyme activity in people with specific CYP3A5 expression variations.[26]

Medicinal uses and Indication

Ibrutinib is indicated for the treatment of the following conditions.

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

·         It is administered to adult patients in the US, whether or not they have a 17p deletion.

·          In individuals with untreated CLL, it is administered either alone or in combination with venetoclax, obinutuzumab, or rituximab in Europe and Canada. It is used either alone or in conjunction with rituximab and bendamustine in individuals who have had at least one previous treatment.

Waldenström's macroglobulinemia

·         It can be taken with rituximab or on its own itself 

·         In Europe, it is authorized for use in first-line treatment for patients who are not candidates for chemoimmunotherapy or for patients who have had at least one previous therapy.

Mantle cell lymphoma (MCL)

·         Ibrutinib is also prescribed in Europe and Canada to treat people with relapsed or refractory MCL

Chronic graft-versus-host disease (cGVHD)

·         It is authorized for use in patients one year of age and older in the United States following the failure of one or more lines of systemic therapy.[27].

·         It is authorized for use in people with steroid-dependent or refractory cGVHD in Canada.[27-29]

Uses in Specified Groups of people:- Women of reproductive potential should refrain from getting pregnant while taking ibrutinib and for up to one month after stopping therapy because it may harm the fetus.
When using ibrutinib and for up to one month after stopping therapy, men should refrain from becoming fathers.
Compared to younger individuals, older patients who took ibrutinib were more likely to experience anemia and grade ≥3 pneumonia.Patients with moderate or severe liver illness are not advised to take ibrutinib since exposure to it rises with liver failure. Patients should have their liver damage closely watched.[30]

Adverse effects

The adverse events listed below correspond to ibrutinib exposure, these patients received 420 mg of ibrutinib daily for a median of 15.6 months.Thirteen percent of individuals experienced adverse responses that required a dose reduction. Ten percent of patients stopped their therapy because of subdural hematomas (four percent) and infectious adverse events (six percent).Diarrhea (63%), bruising (54%), upper respiratory tract infection (48%), hyperuricemia (38%), fatigue (31%), musculoskeletal pain (27%), skin rash (27%), pyrexia (25%), elevated serum creatinine (23%), peripheral edema (23%), constipation (23%), arthralgia (23%), stomatitis (21%), nausea (21%), sinusitis (21%), and dizziness (21%), were the most frequent nonhematological adverse events of any grade severity (20% or higher).

Pneumonia (8%), hypertension (8%), sinusitis (6%), skin infection (6%), dehydration (6%), musculoskeletal discomfort (6%), and atrial fibrillation (5%), were the most frequent grade 3 or higher nonhematological adverse events (5% or more). The most frequent hematological adverse events (20% or more of any grade severity) were anemia (41–44%), neutropenia (47–54%), and thrombocytopenia (71%). Thrombocytopenia and neutropenia of grade 3 or above were observed in 10% and 27% of patients, respectively. [30]

Preclinical Studies

1.      Glioma Research

Ibrutinib's function in inhibiting glioma tumorigenesis and stem cell morphologies was examined in one study. The study showed that glioma cells' capacity to form colonies, migrate, and form spheres was greatly diminished when BTK was down-regulated, either by silencing or by ibrutinib therapy. Mice treated with ibrutinib exhibited less tumors than controls in xenograft models. Furthermore, study of glioma tissue revealed increased BTK expression in cancerous tumors, pointing to BTK as a possible target for treatment.[34]

2.      Central Nervous System Lymphoma

Studies assessed the effectiveness of ibrutinib in treating central nerve system lymphoma (CNSL). According to the study, ibrutinib produced notable therapeutic effectiveness and extended survival in treated mice by reaching high concentrations in the brain and cerebrospinal fluid in murine models.[35].

3.      Hodgkin's Lymphoma

Ibrutinib's anti-tumor activity was evaluated in a study using models of Hodgkin's lymphoma. The results showed that ibrutinib caused apoptosis and reduced cell viability in Hodgkin's lymphoma cell lines. In xenograft models, ibrutinib dramatically reduced tumor growth, down-regulated BTK and associated markers, and triggered autophagy in vivo. These findings provide credence to additional clinical testing of ibrutinib in the management of Hodgkin's lymphoma.[36].

4.      Burkitt Lymphoma

The effects of ibrutinib on Burkitt lymphoma (BL) were investigated in one research. In a preclinical BL model, the study showed that ibrutinib dramatically decreased phospho-BTK levels, inhibited cell growth, and improved overall survival. Clinical trials examining ibrutinib's effectiveness in treating relapsed or refractory BL are under underway as a result of these encouraging findings.[37]

WARNINGS AND PRECAUTIONS FOR IBRUTINIB:

1.      Cardiovascular Risk:

• Arrhythmias and Atrial Fibrillation: Ibrutinib has been linked to a higher risk of atrial fibrillation, which can result in serious side effects like stroke. Patients should be watched for arrhythmia symptoms.

• Hypertension: Ibrutinib treatment may result in elevated blood pressure. Blood pressure should be checked on a regular basis
2. Hemorrhage:

Ibrutinib may raise the risk of bleeding, including potentially fatal and severe conditions such cerebral hemorrhage. Patients on anticoagulants or with a history of bleeding issues should be properly watched.

3.Risk of Infection:

• Enhanced vulnerability to infections: Ibrutinib may weaken the immune system, raising the possibility of opportunistic, viral, fungal, and bacterial infections. Early intervention and preventative care are essential.
• Progressive Multifocal Leukoencephalopathy (PML): Patients on ibrutinib, especially those with long-term immunosuppression, have been documented to have this uncommon but dangerous viral infection of the brain.

4. Liver Toxicity:

• Hepatotoxicity: Regular monitoring of the liver enzymes (AST, ALT) is recommended. Patients with pre-existing liver disorders or those using medications that impact liver metabolism concurrently may have worsening liver dysfunction.

5. Interactions with Drugs:
CYP3A4 Substrates: The cytochrome P450 enzyme CYP3A4 is responsible for the metabolism of ibrutinib. Ibrutinib levels may change when powerful CYP3A4 inhibitors or inducers are used together, which could increase toxicity or reduce efficacy.

6. Renal Impairment:

 Because of decreased medication excretion, patients with renal impairment may need to modify their dosage. Throughout treatment, kidney function must be closely monitored.

7. Lactation and Pregnancy:
• Category D: Pregnancy: Ibrutinib should not be taken unless the advantages outweigh the possible risks. During therapy, both male and female patients are urged to refrain from getting pregnant.
• Lactation: Breastfeeding is not advised during treatment because it is unknown if ibrutinib is eliminated in breast milk.

 8. Second Primary Malignancies:

Patients using ibrutinib have a higher chance of acquiring second primary malignancies, such as skin cancer. It is recommended to screen for new malignancies on a regular basis.

9. Adjusting Doses for Toxicities:
• For some adverse responses, including as severe infections, bleeding episodes, or grade 3/4 toxicities, dose modifications can be required. [38]

CONCLUSION:

Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has revolutionized the treatment of hematologic malignancies, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM). By irreversibly binding to BTK, it disrupts key signaling pathways essential for B-cell survival and proliferation. Clinical trials have demonstrated its efficacy in improving progression-free survival (PFS) and overall survival (OS), making it a preferred alternative to traditional chemotherapy. Despite its advantages, ibrutinib has notable limitations, including adverse effects such as hypertension, bleeding risks, atrial fibrillation, and immunosuppression-related infections. Food intake and drug interactions significantly influence its pharmacokinetics, necessitating careful patient monitoring. Furthermore, resistance mechanisms, such as mutations in BTK, pose challenges in long-term therapy.While ibrutinib is a significant breakthrough, ongoing research focuses on optimizing its combination with other targeted therapies like Venetoclax and Rituximab to enhance efficacy and mitigate resistance. Its impact on oncology highlights the shift towards precision medicine, offering hope for better treatment outcomes in B-cell malignancies.

EFERENCES

1.      Karunakaran P. Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India.

2.      Herman SE, Gordon AL, Hertlein E, et al. Bruton’s tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–96.

3.      Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid. 2013;8:37–45.

4.      Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6:59.

5.      Bhatt V, Alejandro L, Michael A, et al. The promising impact of ibrutinib, a Bruton’s tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy. 2014;34:303–14.

6.      Uppala V, Tabassum A, Lavanya K, Neerja V, Sharma JVC. Method development and validation of ibrutinib by RP-HPLC in bulk and pharmaceutical dosage form. World J Pharm Pharm Sci. 2016;5(5):868–74.

7.      Tomlinson MG, Kurosaki T, Berson AE, Fujii GH, Johnston JA, Bolen JB. Reconstitution of Btk signaling by the atypical Tec family tyrosine kinases Bmx and Txk. J Biol Chem. 1999;274:13577–85.

8.      Mehra S, Nicholls M, Taylor J, Poggi A. The evolving role of Bruton’s tyrosine kinase inhibitors in B cell lymphomas. Int J Mol Sci. 2024;25(14):7516. doi:10.3390/ijms25147516.

9.      Treon S. How I treat Waldenstrom macroglobulinemia. Blood. 2015;126:721–32.

10.  Castillo J, Olszewski A, Kanan S, Meid K, Hunter Z, Treon S. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015;169:81–9.

11.  Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–45.

12.  Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015;372(15):1430–40.

13.  Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.

14.  Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.

15.  Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090–9.

16.  Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842–50.

17.  Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (HELIOS): a randomized, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–11.

18.  Brown JR, Barrientos JC, Barr PM, et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015;125(19):2915–22.

19.  Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–7.

20.  Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, et al. BTK drives ibrutinib resistance via ERK1/2 and protects BTK MYD88-mutated cells by a paracrine mechanism.

21.  Byrd JC, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133:2031–42. doi:10.1182/blood-2018-08-870238.

22.  Stühlinger MC, Weltermann A, Staber P, Heintel D, Nösslinger T, Steurer M. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. Wien Klin Wochenschr. 2020;132(3-4):97–109. doi:10.1007/s00508-019-1534-1.

23.  de Jong J, Sukbuntherng J, Skee D, Murphy J, O'Brien S, Byrd JC. Evaluation of the pharmacokinetics and food effect of oral ibrutinib in healthy subjects and chronic lymphocytic leukemia patients. Blood. 2014 Oct;128(22):4637.

24.  Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, et al. Absorption, metabolism, and excretion of oral 14C-radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015;43(2):289–97.

25.  Solimando DA Jr, Waddell JA. Drug monographs: ibrutinib and ramucirumab. Hosp Pharm. 2014;49(8):702–9.

26.  ChemicalBook. Ibrutinib: Uses, Mechanism of Action and Side Effects. 2024.

27.  FDA. IMBRUVICA (ibrutinib) capsules, tablets, or suspension, for oral use. Approved August 2022.

28.  EMA. Imbruvica (ibrutinib) oral capsules or tablets.

29.  Health Canada. IMBRUVICA (ibrutinib) oral capsules or tablets.

30.  Pharmacyclics, Janssen Biotech. Imbruvica (ibrutinib) capsules/tablets [prescribing information]. Sunnyvale, CA; Horsham, PA; February 2018.

31.  Shakeel F, Iqbal M, Ezzeldin E, Haq N. Thermodynamics of solubility of ibrutinib in ethanol + water cosolvent mixtures at different temperatures. J Mol Liq. 2015;211:375–80. doi:10.1016/j.molliq.2015.06.016.

32.  Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: scientific basis for biowaiver extensions. Pharm Res. 2002;19(7):921–5.

33.  Trunov D, Ižovský J, Beranek J. Characterization of amorphous ibrutinib thermal stability. 2025 Jan 7.

34.  Wei L, Su YK, Lin CM. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (BTK) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget. 2016;7(43):71345–58. doi:10.18632/oncotarget.11572.

35.  Blood. Abstract 4170. 2016;128(22). doi:10.1182/blood.V128.22.4170.4170.

36.  Muqbil I, Chaker M, Aboukameel A, Mohammad RM. Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model. Heliyon. 2019;5(8):e02290. doi:10.1016/j.heliyon.2019.e02290.

37.  Chu Y, Lee S, Shah T, Yin C, Barth M. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma model. OncoImmunology. 2018;7(10):e1512455. doi:10.1080/2162402X.2018.1512455.

38.  The New England Journal of Medicine. Ibrutinib: Mechanisms of Action and Clinical Applications in Hematologic Malignancies.